Coronary Artery Disease
Conditions
Brief summary
AIR STUDY TITLE: Anti-Ischemic effects of Abciximab(Reopro) PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor). INTERVENTION: Heparin vs. heparin + abciximab during PCI PURPOSE: Measure the effects of abciximab on special healing blood stem cells (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on microvascular blood flow. PATIENT ASSESSMENT: 1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28. 2. Measurement of blood flow in selected suitable patients 3. 10 minute questionnaire before discharge and on visit on day 28.
Interventions
DRUGAbciximab
Sponsors
Emory University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
1. Have either: * clinical history of anginal symptoms or positive stress test or * in stent restenosis 2. Have an angiographic \>70% coronary artery stenosis that will be treated with coronary angioplasty or stenting procedure 3. For at least four weeks prior to the procedure have been on, no Hmgcoa- reductase inhibitor or a stable statin dose 4. negative pregnancy test 5. are able to give informed consent
Exclusion criteria
1. Coronary intervention within four weeks prior to enrollment. 2. Treatment with abciximab antagonist within four weeks. 3. treatment with thrombolytic therapy within 48 hours 4. MI within 2 months. 5. recent infections 6. general anesthesia within 3 months. 7. renal failure
Countries
United States
Outcome results
None listed